Doxorubicin (hydrochloride) (Standard)
CAT:
804-HY-15142R-02
Size:
100 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Doxorubicin (hydrochloride) (Standard)
- CAS Number: 25316-40-9
- UNSPSC Description: Doxorubicin (hydrochloride) (Standard) is the analytical standard of Doxorubicin (hydrochloride). This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].
- Target Antigen: ADC Cytotoxin; AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase
- Type: Reference Standards
- Related Pathways: Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;PI3K/Akt/mTOR
- Field of Research: Cancer; Infection
- Assay Protocol: https://www.medchemexpress.com/doxorubicin-hydrochloride-standard.html
- Smiles: COC1=C2C(C(C3=C(C2=O)C(O)=C4C(C[C@](O)(C[C@@H]4O[C@]5(C[C@@H]([C@@H]([C@@H](O5)C)O)N)[H])C(CO)=O)=C3O)=O)=CC=C1.[H]Cl
- Molecular Weight: 579.98
- References & Citations: [1]John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50.|[2]Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8.|[3]P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5.|[4]Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62.|[5]Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21.|[6]Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78.|[7]Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9|[8]Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830.|[9]Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.
- Shipping Conditions: Room Temperature
- Clinical Information: Launched